Upgrades, downgrades, and outlook changes from major analysts.
Coverage of analyst actions including upgrades, downgrades, initiations, and price-target changes. This category tracks how institutional research influences market perception, momentum shifts, and short-term price behavior.
1,376 total articles
Stephens has increased its price target for Business First Bancshares to $35, up from $34, reflecting the company’s strong fourth-quarter results for 2025. The investment firm highlighted the bank's impressive fee income, solid loan growth, and favorable balance sheet repricing as key factors fueling a 10% beat on consensus pre-provision net revenu…
Stephens has increased its price target for Opendoor Technologies to $37 from $35 and kept an Overweight rating, citing anticipated earnings in line with estimates and promising growth prospects. The company’s transition to a new ticker symbol and upcoming analyst day contribute to positive investor sentiment. Meanwhile, Openlane's recent strategic…
Piper Sandler has reaffirmed its Overweight rating and set a $450 price target for Praxis Precision Medicines, citing promising developments in the company's pipeline for essential tremor and developmental epileptic encephalopathies. Despite recent stock surges pushing valuations near their peak, analyst confidence remains strong due to upcoming Ne…
Stephens has increased the price target for United Bankshares Inc. (NASDAQ: UBSI) from $40.00 to $44.00, maintaining an Equal Weight rating. This move follows the company's stronger-than-expected earnings per share of $0.92, surpassing consensus estimates, and highlights solid operational performance including improved asset quality and growth in n…
Scotiabank has elevated its price forecast for Kinder Morgan stock to $30, reflecting robust operational achievements and favorable regulatory progress on key projects. Despite the price adjustment, the stock trades near its upper historical bounds, with momentum indicators suggesting a potential overbought status.
Stephens has increased its price target for Columbia Banking System to $37, signaling approximately 25% upside from its recent trading level. This adjustment follows the bank's strong fourth-quarter earnings which exceeded expectations, alongside promising revenue and net interest income performance. Multiple analysts have similarly raised their pr…
Abbott Laboratories experienced a significant stock price decline following Piper Sandler's decision to reduce its price target from $150 to $135 in response to weaker-than-expected fourth-quarter revenue, primarily driven by challenges in its Nutrition segment. Despite the revenue miss, the company met adjusted earnings per share estimates and sho…
Piper Sandler has adjusted its price target for OFG Bancorp to $43, down from $45, while retaining a Neutral rating. The revision follows a notable share price drop after the company's recent earnings announcement, which analysts attribute to market misinterpretation of seasonal factors in its auto loan segment. The firm also lowered its profit for…
RBC Capital has decreased its price target for CSX Corporation to $39 from $40, noting the company’s recent financial results are broadly in line with expectations despite a sluggish freight market. The railroad reported modest revenue declines and adjusted guidance reflecting low single-digit growth and margin improvements. Analysts remain positiv…
Piper Sandler has raised its price target for Intuitive Surgical to $620, reflecting confidence in the company's solid margin expansion and revenue growth. The surgical robotics firm recently reported better-than-expected fourth-quarter financial results, reinforcing its strong position in the medtech sector. While the stock trades above its fair v…
Piper Sandler has increased its price target on Chipotle Mexican Grill to $47 from $44, citing potential growth momentum in 2026. The firm maintains an Overweight rating, noting that the stock currently trades at a high valuation relative to growth expectations. This revision comes as the market anticipates Chipotle's upcoming earnings report and r…
H.C. Wainwright has upheld its Buy rating on Silence Therapeutics shares, assigning a price target of $75 following discussions with company executives. The firm emphasizes the promising progress of the lead asset divesiran for polycythemia vera, supported by a fully enrolled Phase 2 trial, as well as the broader pipeline advancing toward high-valu…
Ahead of Deckers Outdoor's fiscal third-quarter earnings release, Piper Sandler has upheld its Underweight rating with a price target well below current fair value assessments. While Deckers shows strong revenue growth and robust financial health, apprehensions persist about the long-term prospects of its HOKA brand within the U.S. market and poten…
H.C. Wainwright has confirmed a Buy rating and a $50 price target for Aligos Therapeutics following a recent update on its Phase 2 B-SUPREME clinical trial evaluating pevifoscorvir sodium for chronic hepatitis B. The trial's progress and the company’s strategic initiatives in metabolic liver disease have strengthened investor confidence, while the …
Piper Sandler has reaffirmed an Overweight recommendation for Align Technology, underpinned by a 3.3% year-over-year rise in U.S. clear aligner volumes during December and the likelihood of upward adjustments in earnings forecasts. The firm's target price of $200 signals an 18% gain from current stock levels, with valuation metrics indicating poten…
H.C. Wainwright reaffirmed its Buy stance on Invivyd Inc., maintaining a $10 price target, following a recent dialogue with the company’s leadership. This valuation implies substantial upside relative to the current stock price, reflecting confidence in Invivyd’s forthcoming Phase 3 results for VYD2311 and growth from the PEMGARDA franchise. The co…
H.C. Wainwright has upheld its Buy rating and set a $22.00 price objective for Redwire stock, forecasting significant upside driven by geopolitical dynamics primed to enhance the company's revenue streams by 2026. The firm highlights strong year-to-date performance and transformative defense contract opportunities as key catalysts for Redwire's fut…
KeyBanc has reaffirmed its Overweight rating on JFrog, projecting a 39% upside with a $79 price target ahead of the company’s Q4 earnings announcement scheduled for February 12. The firm highlights growth opportunities driven by AI software development activity and increasing adoption of JFrog’s security products. Broader industry support from anal…
H.C. Wainwright upgraded its price target for Corcept Therapeutics to $105 from $90, maintaining a Buy rating based on encouraging results from the Phase 3 ROSELLA study evaluating relacorilant in platinum-resistant ovarian cancer. The trial demonstrated a significant improvement in overall survival when relacorilant was combined with nab-paclitaxe…
H.C. Wainwright has increased its price target for Spire Global to $19 from $14, citing heightened defense budgets among NATO nations as a major factor influencing this reassessment. Despite a 64.1% year-to-date stock gain outpacing the Russell 2000 by a wide margin, the brokerage foresees continued growth for Spire Global into 2026 fueled by strat…
H.C. Wainwright reaffirmed its Buy rating on uniQure, with a $70 price target signaling significant upside potential despite regulatory hurdles. The firm's outlook follows in-depth meetings with uniQure's leadership, focusing on AMT-130 for Huntington's disease and upcoming FDA engagements. While uniQure faces financial challenges, its strong liqui…
Rosenblatt Securities elevated Intel's price target from $25 to $30 while retaining a Sell rating, reflecting cautious optimism amid the semiconductor firm's strong share price gains and ongoing operational hurdles. Intel shares have surged notably this year but face capacity constraints and a delayed timeline for new foundry customers, resulting i…
H.C. Wainwright has reduced its price target for CorMedix to $13 from $18 while maintaining a Buy rating. The adjustment follows updated 2026-2027 DefenCath sales guidance that influenced the stock's recent pullback. Despite a 36% drop year-to-date, the company's strong gross margins and low P/E ratio underscore its undervaluation. The stock's futu…
Northland has upgraded Intel's price target from $46 to $54, maintaining an Outperform rating driven by recent strong earnings and the company's strategic significance in the U.S. Although first-quarter guidance reflects capacity limitations and supply constraints persist, Intel has produced an impressive 151.83% return over the last year. Broader …
H.C. Wainwright has adjusted its price objective for Plus Therapeutics Inc. from $2.00 down to $1.00 after a recent equity offering by the company. Despite this reduction, the investment bank kept its Buy recommendation, citing upside potential from Plus Therapeutics' current trading price well below its yearly high. The company aims to reach sever…
